| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.7326/0003-4819-119-7_PART_2-199310011-00016 |
| P698 | PubMed publication ID | 8363202 |
| P50 | author | George A. Bray | Q20675488 |
| P433 | issue | 7 Pt 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | obesity | Q12174 |
| appetite | Q28578 | ||
| P304 | page(s) | 707-713 | |
| P577 | publication date | 1993-10-01 | |
| P1433 | published in | Annals of Internal Medicine | Q564416 |
| P1476 | title | Use and abuse of appetite-suppressant drugs in the treatment of obesity | |
| P478 | volume | 119 |
| Q37579994 | A Case-Based Look at Healthy Weight Loss for Survivors of Cancer |
| Q31510470 | A concise review on the therapeutics of obesity |
| Q80188722 | A pharmacological analysis of stimulant-induced increases in smoking |
| Q33542534 | A risk-benefit assessment of anti-obesity drugs |
| Q34333564 | Amphetamine-induced chorea in attention deficit-hyperactivity disorder |
| Q75229769 | Behavioral treatment of obesity |
| Q33904983 | Behavioral treatment of obesity |
| Q47743129 | Beneficial effects of Tai Chi for amphetamine-type stimulant dependence: a pilot study |
| Q40263189 | Biodegradable Polymeric Microsphere-Based Drug Delivery for Inductive Browning of Fat. |
| Q44786599 | Case report of abuse of Orlistat |
| Q71769028 | Comparison of the costs associated with medical and surgical treatment of obesity |
| Q35992004 | Contemporary approaches into obesity: drugs and genes |
| Q44300449 | Curiosities in drug metabolism. |
| Q33684253 | Current concepts in the pharmacological management of obesity |
| Q40986157 | Current views on obesity |
| Q41445495 | Dexfenfluramine. An updated review of its therapeutic use in the management of obesity |
| Q35985023 | Does co-morbid depression alter the inverse relationship between obesity and substance use disorders? |
| Q40377837 | Effect of methamphetamine on the pharmacokinetics of dextromethorphan and midazolam in rats |
| Q44739272 | Effects of acute and chronic administration of fenproporex on DNA damage parameters in young and adult rats |
| Q38717129 | Epidemiology of Obesity and Pharmacologic Treatment Options |
| Q41026126 | Evaluation of drugs for treating obesity |
| Q34459132 | Exposure to a high-fat diet decreases sensitivity to Δ9-tetrahydrocannabinol-induced motor effects in female rats |
| Q47592185 | Hoping to maintain a balance: the concept of hope and the discontinuation of anorexiant medications |
| Q47325422 | How safe is the use of herbal weight-loss products sold over the internet? |
| Q35027761 | Inhibition of gastric emptying and intestinal transit by amphetamine through a mechanism involving an increased secretion of CCK in male rats |
| Q34137620 | Interaction of the anorectic medication, phendimetrazine, and its metabolites with monoamine transporters in rat brain |
| Q34797774 | Khat use and appetite: an overview and comparison of amphetamine, khat and cathinone. |
| Q51103688 | Lifestyle modification in the pharmacologic treatment of obesity: a pilot investigation of a potential primary care approach. |
| Q39798263 | Long-term effects of gastric bypass surgery on psychosocial well-being and eating behavior: not all that glitters is gold. |
| Q41284565 | Medicating the obese patient |
| Q28472559 | Methamphetamine self-administration is associated with persistent biochemical alterations in striatal and cortical dopaminergic terminals in the rat |
| Q34795068 | Modafinil effects on reinstatement of methamphetamine seeking in a rat model of relapse |
| Q34662295 | Neurocognitive effects of methamphetamine: a critical review and meta-analysis |
| Q42864716 | Oral administration of GZ-793A, a VMAT2 inhibitor, decreases methamphetamine self-administration in rats |
| Q33584142 | Outcomes of pharmacological and surgical treatment for obesity |
| Q34585198 | Pharmacological approaches for the treatment of obesity |
| Q21296814 | Pharmacotherapies for obesity: past, current, and future therapies |
| Q73741112 | Pharmacotherapy for obesity |
| Q81887900 | Pharmacotherapy for obesity |
| Q82208096 | Pharmacotherapy for obesity |
| Q35905513 | Psychiatric medication-induced obesity: treatment options |
| Q34163070 | Psychostimulant dependence in a community sample. |
| Q35843533 | Psychotropic drugs in the treatment of obesity: what promise? |
| Q34026742 | Rise and fall of anti-obesity drugs |
| Q34016243 | Safety of antiobesity drugs |
| Q39538570 | Serious adverse events reported for antiobesity medicines: postmarketing experiences from the EU adverse event reporting system EudraVigilance. |
| Q48792378 | Sertraline and relapse prevention training following treatment by very-low-calorie diet: a controlled clinical trial |
| Q47320279 | Sertraline enhances the effects of cognitive-behavioral treatment on weight reduction of obese patients |
| Q47268542 | Sibutramine produces dose-related weight loss |
| Q41026257 | Sibutramine: a novel new agent for obesity treatment |
| Q36288031 | The cannabinoid CB1 receptor antagonist AM251 does not modify methamphetamine reinstatement of responding |
| Q42540665 | The fen-phen finale: a study of weight loss and valvular heart disease |
| Q45188954 | The long-term management of obesity with continuing pharmacotherapy |
| Q85297986 | The uphill battle facing antiobesity drugs |
| Q41707222 | Update on the pharmacotherapy of obesity |
| Q36781041 | Use of intracranial self-stimulation to evaluate abuse-related and abuse-limiting effects of monoamine releasers in rats |
| Q34557537 | Weight gain, obesity, and psychotropic prescribing |
Search more.